We help bridge the ‘valley of death’ between basic research and industry, providing our industry partners with a pipeline of commercially viable projects and services.
We have extensive experience commercialising academic research having helped launch 12 drugs including Avastin®, Campath® and Herceptin®, and form 18 start-ups including the UK’s largest and most successful biotech companies, Celltech and CAT. We have negotiated more than 400 commercial licences, with global pharma and biotech revenues from this research being over £50 billion.